II期和III期皮肤黑色素瘤的流行病学和生存结局:一项系统综述。

IF 1 Q4 ONCOLOGY

Melanoma Management Pub Date : 2020-03-19 DOI:10.2217/mmt-2019-0022

Rachael Miller, Sophie Walker, Irene Shui, Agnes Brandtmüller, Kevin Cadwell, Emilie Scherrer

{"title":"II期和III期皮肤黑色素瘤的流行病学和生存结局:一项系统综述。","authors":"Rachael Miller, Sophie Walker, Irene Shui, Agnes Brandtmüller, Kevin Cadwell, Emilie Scherrer","doi":"10.2217/mmt-2019-0022","DOIUrl":null,"url":null,"abstract":"Aim: Management of cutaneous melanoma (CM) is continually evolving with adjuvant treatment of earlier stage disease. The aim of this review was to identify published epidemiological data for stages II-III CM.Materials & methods: Systematic searches of Medline and Embase were conducted to identify literature reporting country/region-specific incidence, prevalence, survival or mortality outcomes in stage II and/or III CM. Screening was carried out by two independent reviewers.Results & conclusion: Of 41 publications, 14 described incidence outcomes (incidence rates per stage were only reported for US and Swedish studies), 33 reported survival or mortality outcomes and none reported prevalence data. This review summarizes relevant data from published literature and highlights an overall paucity of epidemiological data in stages II and III CM.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2020-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2019-0022","citationCount":"33","resultStr":"{\"title\":\"Epidemiology and survival outcomes in stages II and III cutaneous melanoma: a systematic review.\",\"authors\":\"Rachael Miller, Sophie Walker, Irene Shui, Agnes Brandtmüller, Kevin Cadwell, Emilie Scherrer\",\"doi\":\"10.2217/mmt-2019-0022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: Management of cutaneous melanoma (CM) is continually evolving with adjuvant treatment of earlier stage disease. The aim of this review was to identify published epidemiological data for stages II-III CM.Materials & methods: Systematic searches of Medline and Embase were conducted to identify literature reporting country/region-specific incidence, prevalence, survival or mortality outcomes in stage II and/or III CM. Screening was carried out by two independent reviewers.Results & conclusion: Of 41 publications, 14 described incidence outcomes (incidence rates per stage were only reported for US and Swedish studies), 33 reported survival or mortality outcomes and none reported prevalence data. This review summarizes relevant data from published literature and highlights an overall paucity of epidemiological data in stages II and III CM.\",\"PeriodicalId\":44562,\"journal\":{\"name\":\"Melanoma Management\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2020-03-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/mmt-2019-0022\",\"citationCount\":\"33\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Melanoma Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/mmt-2019-0022\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/mmt-2019-0022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 33

摘要

目的:随着早期疾病的辅助治疗，皮肤黑色素瘤(CM)的治疗不断发展。本综述的目的是确定已发表的II-III期CM的流行病学数据。材料和方法:对Medline和Embase进行系统检索，以确定报告国家/地区特定发病率、患病率、II期和/或III期CM的生存或死亡结果的文献。筛选由两名独立评审员进行。结果和结论:在41篇出版物中，14篇描述了发病率结果(仅报道了美国和瑞典研究的每个阶段的发病率)，33篇报道了生存或死亡率结果，没有报道患病率数据。本综述总结了来自已发表文献的相关数据，并强调了II期和III期CM的流行病学数据的总体缺乏。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Epidemiology and survival outcomes in stages II and III cutaneous melanoma: a systematic review.

Aim: Management of cutaneous melanoma (CM) is continually evolving with adjuvant treatment of earlier stage disease. The aim of this review was to identify published epidemiological data for stages II-III CM.

Materials & methods: Systematic searches of Medline and Embase were conducted to identify literature reporting country/region-specific incidence, prevalence, survival or mortality outcomes in stage II and/or III CM. Screening was carried out by two independent reviewers.

Results & conclusion: Of 41 publications, 14 described incidence outcomes (incidence rates per stage were only reported for US and Swedish studies), 33 reported survival or mortality outcomes and none reported prevalence data. This review summarizes relevant data from published literature and highlights an overall paucity of epidemiological data in stages II and III CM.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.